PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells According to Frost & Sullivan - An increased number of diseases that are either incurable or difficult to treat allures clinicians to the approach of stem cell therapy
Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells According to Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2008/10/21 - An increased number of diseases that are either incurable or difficult to treat allures clinicians to the approach of stem cell therapy.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Highly prized, due to their therapeutic potential, stem cell therapies are believed to treat a wide variety of diseases. Stem cell research progresses at a fast pace; however, both adult and embryonic stem cells have their own unique challenges that must be overcome before therapies make it to the market.

New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Stem Cell Market - Current Developments, provides insights and analysis on stem cell therapeutic development in the U.S., including the clinical trial pipeline, key market drivers and challenges, and the market potential for stem cell therapy in selected disease indications. In this research, Frost & Sullivan's expert analysts thoroughly examine this cutting-edge healthcare technology market.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of U.S. Stem Cell Market - Current Developments, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.

“New research into stem cell therapies has resulted in several technological innovations that have improved the manufacturing and design of these products,” notes Frost & Sullivan Research Analyst Katheryn Symank. “For example, improvements in cell sorting and cell culture have allowed for improved survival and growth of adult stem cells. This allows for the rapid production of a high-quality adult stem cell product with increased bio-availability that may be produced on a large scale.”

Adult stem cell therapies were traditionally thought to have poor therapeutic potential because they could only be produced in limited quantities or as needed. Now adult stem cells have the potential to become standardized pre-made therapies that can be mass produced.
However, both stem cell types have challenges and technical difficulties that impede product development. Embryonic stem cells, while hailed for their promise as potential therapies, are immersed in both political and ethical controversy. In addition, some researchers have questioned the safety of embryonic stem cells in humans, while adult stem cells require a high degree of technical expertise because they are difficult to culture and lose potency over time.
”Both embryonic stem cells and adult stem cells have their own challenges that must be overcome,” explains Symank. “The controversy surrounding embryonic stem cells has resulted in severe limitations in federal funding for their research, while adult stem cells are often viewed as having less therapeutic potential because they can differentiate into a limited number of cells.”

New evidence suggests that adult stem cells may actually have more plasticity than once thought, and may actually derive more tissue types. In addition, new technical innovations allow for adult stem cells to be cultured in large quantities without the loss of potency. In regards to embryonic stem cells, despite the severe limitations in federal funding, support from private sources and individual states have allowed research to progress at a fast pace. However, there have been concerns over the safety of the use of embryonic stem cells in humans because of potential adverse consequences from undifferentiated cells.

”In order to ensure the safety of embryonic stem cell products in humans, strict manufacturing regulations may need to be imposed by the FDA,” advises Symank. “In addition, there could be strict product safety testing in place to guarantee their safety.”

U.S. Stem Cell Market: Current Developments is part of the Pharmaceuticals and Biotechnology subscription, which also includes research in the following markets: Biopharmaceuticals, Specialty Pharmaceuticals, Contract Research and Manufacturing, Vaccines, and Drug Delivery. Recent titles include: U.S. Biotechnology – Therapeutic Monoclonal Antibodies Market, U.S. Contract Research Outsourcing Market, European Biosimilars Market Outlook and U.S. Human Growth Hormone Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells According to Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)